Notice of Interim Report
17/08/2022 12:00
For best results when printing this announcement, please click on link below: http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220817:nRSQ3392Wa&default-theme=true RNS Number : 3392W RTW Venture Fund Limited 17 August 2022 LEI: 549300Q7EXQQH6KF7Z84 17 August 2022 RTW Venture Fund Limited Notice of Interim Report RTW Venture Fund Limited (the "Company") advises that it will publish its Interim Report for the six months ended 30 June 2022 (the "Interim Report") on 15 September 2022. A conference call for analysts and shareholders will be held at 2 pm BST / 9 am EST on the day. To register for the event please RSVP to georgeb@buchanan.uk.com (mailto:georgeb@buchanan.uk.com) or IR@rtwfunds.com (mailto:IR@rtwfunds.com) . For Further Information RTW Investments, LP +44 (0)771 741 7711 Stephanie Sirota, Chief Business Officer Woody Stileman, Managing Director, Strategic Partnerships Buchanan +44 (0)20 7466 5000 Charles Ryland Henry Wilson George Beale About RTW Venture Fund Limited: RTW Venture Fund Limited (LSE: RTW & RTWG) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Venture Fund invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Venture Fund Limited is managed by RTW Investments, LP, a leading US healthcare investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies. Visit the RTW website at www.rtwfunds.com (https://protect.mimecast-offshore.com/s/eY8OCgLEp4SlY4JEFN_vEF) for more information. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com (mailto:rns@lseg.com) or visit www.rns.com (http://www.rns.com/) . RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy) . END NORFLFLITRIDLIF